Two National Guard members shot near White House
DUBLIN - Goldman Sachs & Co. LLC has disclosed its trading positions in Avadel Pharmaceuticals PLC (NASDAQ:AVDL) as required under Irish takeover regulations, according to a regulatory filing published Tuesday.
The filing shows that as of November 24, 2025, Goldman Sachs held a long position of 1,034,837 shares, representing approximately 1.06% of Avadel Pharmaceuticals, and a short position of 575,237 shares, equivalent to about 0.59% of the company.
The disclosure details multiple transactions conducted on November 24, including purchases of Avadel shares at prices ranging from $23.0950 to $23.1000 per share. The filing also documents various securities lending activities, including loan returns and new borrowing arrangements.
Goldman Sachs reported derivatives transactions, specifically reducing a long CFD (Contract for Difference) position by 1,145 securities at a price of $22.9938 per unit. The firm also disclosed open swap positions set to expire in December 2025 and January 2026.
The disclosure was made in compliance with Rule 38.5(b) of the Irish Takeover Panel Act, which requires exempt principal traders to report their dealings in relevant securities during takeover periods. Goldman Sachs is serving as an advisor to Avadel Pharmaceuticals in connection with a potential takeover situation, according to the filing.
The regulatory submission was made through the Regulatory News Service (RNS) of the London Stock Exchange.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.